Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62


Alpha1-antitrypsin inhibits angiogenesis and tumor growth.

Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, Volpert OV.

Int J Cancer. 2004 Dec 20;112(6):1042-8.


TNF-alpha-induced self expression in human lung endothelial cells is inhibited by native and oxidized alpha1-antitrypsin.

Subramaniyam D, Virtala R, Pawłowski K, Clausen IG, Warkentin S, Stevens T, Janciauskiene S.

Int J Biochem Cell Biol. 2008;40(2):258-71. Epub 2007 Aug 6.


CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.


Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.

Zhang GM, Zhang YM, Fu SB, Liu XH, Fu X, Yu Y, Zhang ZY.

Chin Med J (Engl). 2008 Nov 20;121(22):2324-30.


The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.

Sini P, Wyder L, Schnell C, O'Reilly T, Littlewood A, Brandt R, Hynes NE, Wood J.

Clin Cancer Res. 2005 Jun 15;11(12):4521-32.


Headpin: a serpin with endogenous and exogenous suppression of angiogenesis.

Shellenberger TD, Mazumdar A, Henderson Y, Briggs K, Wang M, Chattopadhyay C, Jayakumar A, Frederick M, Clayman GL.

Cancer Res. 2005 Dec 15;65(24):11501-9.


The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.

He GA, Luo JX, Zhang TY, Hu ZS, Wang FY.

Biochem Biophys Res Commun. 2004 May 28;318(2):354-60.


N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth.

Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada K, Tontsch U, Klenk M, Yamauchi-Takihara K, Ziche M, Rofstad EK, Schweigerer L, Fotsis T.

Oncogene. 2002 May 16;21(22):3552-61.


Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.

Struyf S, Salogni L, Burdick MD, Vandercappellen J, Gouwy M, Noppen S, Proost P, Opdenakker G, Parmentier M, Gerard C, Sozzani S, Strieter RM, Van Damme J.

Blood. 2011 Jan 13;117(2):480-8. doi: 10.1182/blood-2009-11-253591. Epub 2010 Oct 27.


SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo.

Chao WR, Amin K, Shi Y, Hobbs P, Tanabe M, Tanga M, Jong L, Collins N, Peters R, Laderoute K, Dinh D, Yean D, Hou C, Sato B, Alt C, Sambucetti L.

Angiogenesis. 2011 Mar;14(1):1-16. doi: 10.1007/s10456-010-9191-z. Epub 2010 Nov 21.


Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.

Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, Majest SM, McKay LM, Haskell CJ, Bell RL, Nguyen B, Marsh KC, Surber BW, Uchic JT, Ferrero J, Wang YC, Leal J, Record RD, Hodde J, Badylak SF, Lesniewski RR, Henkin J.

J Med Chem. 2005 Apr 21;48(8):2838-46.


Interaction of the human serine protease inhibitor alpha-1-antitrypsin with Cryptosporidium parvum.

Forney JR, Yang S, Healey MC.

J Parasitol. 1996 Jun;82(3):496-502.


Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin.

Janciauskiene S, Larsson S, Larsson P, Virtala R, Jansson L, Stevens T.

Biochem Biophys Res Commun. 2004 Aug 27;321(3):592-600.


Paradoxic effects of metformin on endothelial cells and angiogenesis.

Dallaglio K, Bruno A, Cantelmo AR, Esposito AI, Ruggiero L, Orecchioni S, Calleri A, Bertolini F, Pfeffer U, Noonan DM, Albini A.

Carcinogenesis. 2014 May;35(5):1055-66. doi: 10.1093/carcin/bgu001. Epub 2014 Jan 13.


Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?

Ortiz G, Salica JP, Chuluyan EH, Gallo JE.

Biol Res. 2014 Nov 18;47:58. doi: 10.1186/0717-6287-47-58. Review.


Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway.

Cai WB, Zhang Y, Cheng R, Wang Z, Fang SH, Xu ZM, Yang X, Yang ZH, Ma JX, Shao CK, Gao GQ.

PLoS One. 2012;7(12):e53152. doi: 10.1371/journal.pone.0053152. Epub 2012 Dec 31.


Protein C and its inhibitor in malignancy.

Suzuki K, Hayashi T.

Semin Thromb Hemost. 2007 Oct;33(7):667-72. Review.


Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.

Wang L, Shi WY, Yang F, Tang W, Gapihan G, Varna M, Shen ZX, Chen SJ, Leboeuf C, Janin A, Zhao WL.

Haematologica. 2011 Jun;96(6):927-31. doi: 10.3324/haematol.2010.037689. Epub 2011 Feb 17.


Divergent effects of alpha1-antitrypsin on neutrophil activation, in vitro.

Janciauskiene S, Zelvyte I, Jansson L, Stevens T.

Biochem Biophys Res Commun. 2004 Mar 5;315(2):288-96.


Supplemental Content

Support Center